Ya I know Sanofi has a marketing problem. However the drug is better than lovenox and if they would market and price they could blow their numbers out. This company is cheap. I talked to a leader in oncology and he said of all the companies this one (Sanofi) is almost impossible to deal with. Too bad they couldn't get a marketing partner and spend some money! They have the products!
I've been following Atrix for a long time. SNY has the marketing rights on Atrix's Eligard product for prostate cancer.
Sanofi will be taking on Lupron(from Abbott) in the upcoming marketing battle once the 90 day version of Eligard gets approved.
Eligard has Lupron beat in every category that counts: efficacy, side-effects, and ease of administration.
Atrix expects final FDA approval before the end of September, and I wonder if anyone would hazard a guess as to what sales might be next year.
Also, if SNY is going to be aggressive in cancer, a company called GenVec(GNVC) is looking for a partner on its revolutionary cancer treatment called TNFerade. Phase I results were almost too good to be true, and now they are going to Phase II.
I know from comments that Atrix has made that Sanofi is a top-flight company--smart, aggressive, and looking for new products. GNVC would be a good place to look, although there is still some clinical risk to bear if they get involved.